What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Diabetes mellitus
- Type 2 diabetes
His primary areas of study are Internal medicine, Diabetes mellitus, Endocrinology, Type 2 diabetes and Pharmacology.
His biological study spans a wide range of topics, including Gastroenterology, Placebo and Surgery.
His Diabetes mellitus study combines topics from a wide range of disciplines, such as Psychiatry and Schizophrenia.
His Endocrinology study frequently draws connections between adjacent fields such as Rimonabant.
In his study, which falls under the umbrella issue of Type 2 diabetes, Pioglitazone and Diabetes risk is strongly linked to Insulin resistance.
His research in Pharmacology intersects with topics in Sitagliptin, Saxagliptin, Canagliflozin and Kidney disease.
His most cited work include:
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. (3386 citations)
- Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study (1368 citations)
- Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes (868 citations)
What are the main themes of his work throughout his whole career to date?
André Scheen focuses on Internal medicine, Endocrinology, Diabetes mellitus, Type 2 diabetes and Gynecology.
The study incorporates disciplines such as Surgery and Cardiology in addition to Internal medicine.
His study in Obesity, Glucagon, Glucose tolerance test and Carbohydrate metabolism is carried out as part of his studies in Endocrinology.
His studies deal with areas such as Disease, Pediatrics and Risk factor as well as Diabetes mellitus.
André Scheen has researched Type 2 diabetes in several fields, including Metformin, Intensive care medicine, Metabolic syndrome, Pharmacology and Type 2 Diabetes Mellitus.
The Gynecology study combines topics in areas such as Coronary heart disease and Nutritional status.
He most often published in these fields:
- Internal medicine (44.43%)
- Endocrinology (28.76%)
- Diabetes mellitus (25.33%)
What were the highlights of his more recent work (between 2015-2021)?
- Type 2 diabetes (24.08%)
- Internal medicine (44.43%)
- Diabetes mellitus (25.33%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Type 2 diabetes, Internal medicine, Diabetes mellitus, Gynecology and Metformin.
His Type 2 diabetes research is multidisciplinary, relying on both Heart failure, Kidney disease, Insulin, Disease and Pharmacology.
His Pharmacology study combines topics in areas such as Saxagliptin, Pharmacotherapy and Glucagon-like peptide 1 receptor.
His Internal medicine study incorporates themes from Endocrinology, Cardiology and Type 2 Diabetes Mellitus, Empagliflozin, Dapagliflozin.
His work in Diabetes mellitus addresses subjects such as Placebo, which are connected to disciplines such as Clinical trial.
His Metformin research is multidisciplinary, incorporating perspectives in Sulfonylurea, Randomized controlled trial, Gliflozin and Oncology.
Between 2015 and 2021, his most popular works were:
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial (555 citations)
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial (237 citations)
- Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial (145 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Diabetes mellitus
- Type 2 diabetes
André Scheen mostly deals with Type 2 diabetes, Internal medicine, Diabetes mellitus, Type 2 Diabetes Mellitus and Pharmacology.
His Type 2 diabetes research incorporates themes from Metformin, Hypoglycemia, Diuretic, Intensive care medicine and Disease.
The various areas that he examines in his Internal medicine study include Empagliflozin, Endocrinology and Cardiology.
The various areas that he examines in his Endocrinology study include Bone metastasis, Prostate cancer and Rheumatology.
His Diabetes mellitus study combines topics from a wide range of disciplines, such as Stroke, Adverse effect, Clinical trial and Insulin.
His Type 2 Diabetes Mellitus research is multidisciplinary, incorporating perspectives in Institutional repository, Weight loss, Kidney disease, Overweight and Evidence-based practice.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
